Significant differences in the level of extrahepatic inflammation between NASH-patients, e.g., lower levels of adipose tissue inflammation observed in NAFLD patients with the PNPLA3 I148M genetic variant as compared to weight-matched NAFLD patients homozygous for the wild type allele (170), may therefore cause the observed discrepancies between various published studies. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.